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emerged as a major complication of bortezomib therapy, which usu-
ally appears in the first courses of therapy with a number of sensory 
and painful symptoms, including reduced threshold to mechanical 
and cold stimuli. No satisfactory explanation or effective treatment 
exists for bortezomib-evoked CIPN.
Patients (or Materials) and Methods: In this study, we evaluated 
whether TRPA1 acted as a critical mediator of CIPN by bortezomib 
or oxaliplatin in a mouse model system.
Results: Our data demonstrated that CIPN hypersensitivity pheno-
type that was stably established by bortezomib could be transiently 
reverted by systemic or local treatment with the TRPA1 antagonist 
HC-030031. A similar effect was produced by the oxidative stress 
scavenger α -lipoic acid. Notably, the CIPN phenotype was abolished 
completely in mice that were genetically deficient in TRPA1, high-
lighting its essential role. Administration of bortezomib or oxalipl-
atin, which also elicits TRPA1-dependent hypersensitivity, produced 
a rapid, transient increase in plasma of carboxy-methyllysine, a by-
product of oxidative stress. Short-term systemic treatment with either 
HC-030031 or α -lipoic acid could completely prevent hypersensitiv-
ity if administered before the cytotoxic drug.
Conclusion: Our findings highlight a key role for early activation/
sensitization of TRPA1 by oxidative stress by-products in producing 
CIPN. Furthermore, they suggest prevention strategies for CIPN in 
patients through the use of early, short-term treatments with TRPA1 
antagonists.
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Introduction: Tanacetum parthenium L. (feverfew) has long been 
known as a migraine remedy and, according to positive results of 
clinical trials, it is currently recommended for migraine prevention. 
However, the mechanism responsible for such protective action 
remains unknown. Parthenolide, a major ingredient of feverfew, is 
a reactive molecule that can interact with nucleophilic sites of tran-
sient receptor potential ankyrin 1 (TRPA1). Thus, we hypothesized 
that parthenolide inhibits TRPA1 channel on peptidergic trigeminal 
nerves.
Patients (or Materials) and Methods: Experiments were performed 
in vitro in human and mouse cultured cells/neurons and rat isolated 
tissues, and in in vivo in rats and wild-type and TRPA1-deficient 
mice. Electrophysiologic, calcium, neuropeptide release, smooth 
muscle motility, allodynic and nociceptive responses, and changes in 
meningeal blood flow were evaluated.
Results: Parthenolide selectively activates recombinant (trans-
fected cells) or natively expressed (rat/mouse trigeminal neurons) 
TRPA1, and, by targeting TRPA1, activates trigeminal nerve end-
ings. However, parthenolide behaves as a partial agonist at neuronal 
TRPA1 of the rat urinary bladder, desensitizes the recombinant 
TRPA1, and, after initial stimulation, renders peptidergic, TRPA1-
expressing nerve terminals unresponsive to any stimulus. These 
effects causes abrogation of nociceptive responses evoked by TRPA1 
agonists, and inhibition of calcitonin gene-related peptide (CGRP) 
release from trigeminal neurons, and, in particular, of CGRP-mediated 
meningeal vasodilatation evoked by TRPA1 stimulants and other 
mechanisms.
Conclusion: Peculiar features of parthenolide (TRPA1 partial ago-
nism, channel desensitization, and defunctionalisation of peptidergic 
primary sensory neurons), ultimately resulting in the inhibition of 
CGRP release from trigeminal neurons, may contribute to the anti-
migraine effect of feverfew.
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Introduction: Facilitation of spinal GABAergic inhibition with 
benzodiazepines (BZD) reverses pain sensitization in rodents. 
In human, the use of BZD in pain is limited by their sedative 
effect. We previously demonstrated the antihyperalgesic effect of 
clobazam, a 1,5-BZD, in mice and its lack of sedation at effective 
doses. Hence we designed a pharmacokinetic-pharmacodynamic 
study to explore the effect of antihyperalgesic effect of BZD in 
healthy volunteers.
Patients (or Materials) and Methods: Randomized, double-blind, 
crossover controlled study in 25 healthy volunteers comparing 
clobazam 20 mg with clonazepam 1 mg (positive control) and 
tolterodine 1.37 mg (active placebo) 2 weeks apart. The primary 
outcome was the effect on the size of secondary hyperalgesia elicited 
by the UVB irradiation of the skin of the forearm (sunburn model). 
Quantitative sensory testing, nociceptive flexion reflex, and the cold 
pressor test were also performed. Sedation was measured by a visual 
analog scale (VAS), the digit substitution symbol test (DSST), and 
saccadic eye movements (SEM) recording. Blood samples were taken 
to determine the pharmacokinetic of clobazam.
Results: We observed a reduction of the area of the secondary 
hyperalgesia with clobazam and clonazepam. The maximum of the 
effect was seen at t = 2 hours (median of the difference between t 
= 2 and baseline [MOD2-0] [+/-CI] vs placebo: 19.2 cm2 (–2.7-
37.9) P = 0.07 for clobazam and 29.6 cm2 (2.0-55.1), P = 0.03, 
for clonazepam), in line with the expected Tmax of the compounds. 
Regarding sedation, at t = 2 hours, we saw an effect of the 2 active 
compounds on the VAS (MOD2-0 [+/-CI] vs placebo: 14 mm (1.0-
21.5), P = 0.03 for clobazam and 26 mm (14.0-37.5), P < 0.001 
for clonazepam) and on the peak velocity of the SEM (MOD2-0 
[+/-CI] vs placebo: 30.8 deg./s. (6.6-60.6), P < 0.01 for clobazam 
and 55.2 deg./s.(24.5–85.0), P < 0.01 for clonazepam]. The DSST 
was only impaired by clonazepam (MOD2-0 [+/-CI] vs placebo: 
11.0 (5.0–18.0), P = 0.03). These effects disappeared at t = 8 hours 
except that clonazepam still impaired SEM (median of the differ-
ence between t = 8 and baseline [+/-CI] vs placebo: 28.3 deg./s. 
(5.3–52.7), P = 0.01).
Conclusion: Clobazam and clonazepam decreased the area of sec-
ondary hyperalgesia in the sunburn model, which suggests that 
GABAA receptor ligands are involved in the modulation of pain 
sensitization in human. Clobazam was less sedative than clonaz-
epam and therefore a suitable “tool compound” to assess the role of 
GABAergic pathways in human.
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Introduction: N-methyl-D-aspartate receptor (NMDAR) antago-
nists are used for postsurgery neuropathic pain states, but severe side 
effects limit their clinical use. Memantine, when given after surgery, 
shows contradictory results as regards neuropathic pain alleviation.
Patients (or Materials) and Methods: Memantine is administered 
in animals before or after spinal nerve ligation (SNL) to evaluate 
the antinociceptive/cognitive effects and associated molecular events 
(including phosphorylated-Tyr1472NR2B subunit). SNL animals 
received memantine or saline 4 days before (pre-emptive) or after 
surgery (postoperative) for 7 days, were tested for tactile allodynia, 
mechanical hyperalgesia, cognitive function and spinal cord molecu-
lar events, and results were compared (significance P < 0.05).
Results: Postoperative memantine had no beneficial effect on tac-
tile allodynia, mechanical hyperalgesia, or spatial memory, and 
molecular expression of NR2B subunit was significantly increased. 
Pre-emptive memantine prevented the development of mechanical 
hyperalgesia, tactile allodynia, and impairment of spatial memory; 
spinal pTyr1472NR2B was not increased.
Conclusion: Blockade of NMDAR by memantine 4 days before sur-
gery rather than postoperatively is a promising strategy in animals to 
alleviate neuropathic pain development and impairment of cognitive 
function. The pivotal role of pTyr1472NR2B must be studied further, 
and confirmation of these findings in patients would constitute a 
giant footstep in the prevention of neuropathic pain that frequently 
follows surgical procedures.
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Introduction: With > 25% of the American population experiencing 
daily pain and the number of new drugs still in the single-digit area, it 
is becoming more and more of an important health problem to come 
up with new or improved analgesis compounds. Our paper proposes 
a new approach for obtaining an efficient controlled-release system 
for the pain treatment via inovative polymeric nanoparticles by using 
an interfacial condensation method between a natural polymer, chi-
tosan (CS) and a synthetic one (poly (maleic anhydride -alt -vinyl 
acetate), (poly (MAVA).
Patients (or Materials) and Methods: Chitosan, acetone, Ibuprofen 
(IBU), hexane, and surfactants were used (Sigma Aldrich). The alter-
nant copolymer – poly (MAVA) was synthesized by radical copolym-
erization and characterized in our laboratory. The nanocapsules were 
characterized and investigated by Fourier transform infrared spec-
troscopy (FTIR), Scanning Electron Microscope (SEM), Transmission 
Electron Microscope (TEM), thermogravimetric analysis (TGA), and 
differential scanning calorimetry (DSC). In vitro IBU loading and 
release was also investigated. In vivo testing of IBU/nanocapsules 
was evaluated by hot plate test and tail flick test, behavioral tests 
that quantify the thermal nociception. Adult male Swiss mice in dif-
ferent groups of 8 mice each were intraperitoneally injected with 
one of the following formulations: 0.9% saline for a control group; 
ibuprofen for positive control group (100 mg/kg b.w.); ibuprofen-
loaded nanocapsules (MAVA-CS-9) for test group (100 mg/kg b.w. 
equivalent ibuprofen). Inhibition to pain stimuli was then calculated.
Results: Zeta potential determinations indicated a good stability of 
the nanocapsules in aqueous solutions. Scanning electron micros-
copy confirmed the nanometric dimensions and the spherical shape 
of the nanocapsules. The thermal properties achieved by DSC and 
ATG showed the nanocapsules’ good thermal stability. In addition, 
these systems present a good swelling capacity, which is influenced by 
the reaction parameters taken into account in this study. The drug-
loading and -release capacity (studied for ibuprofen sodium salt used 
as water-soluble drug) is controlled by the diffusion speed through 
the polymeric membrane and is influenced by the swelling degree. 
Although ibuprofen alone has a half-life of 1 to 3 hours, and previ-
ous studies showed an analgesic improvement of their nanoparticle 
formulations in the 1- to 2-hour range, our system has a time interval 
of 2 to 6 hours of analgesic efficacy, an increase of up to 6 times the 
reference ibuprofen formulation.
Conclusion: We have proved the possibility of a sustained-release 
system for central pain inhibition (from 2 to 24 hours) versus 0 to 
2 hours ibuprofen control. Future variations in the ibuprofen load 
of the nanocapsules could yield potentially significant commercial 
applications with improved efficacy and safety profiles.
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Introduction: It known that bile acids improve the absorption, bio-
availability, and pharmacodynamic characteristics of some drugs. 
Because morphine analgesia is produced by activation of opioid 
receptors within the central nervous system at both spinal and 
supraspinal levels, and because morphine molecule contains 3 polar 
groups, and as such is hard to transfer through the blood-brain bar-
rier, the aim of the study was to examine the potential influence 
of bile acids derivates, namely sodium salt of monoketocholic acid 
(MKH-Na) and methyl ester of monoketocholic acid (MKH-Me) on 
analgesic effect of morphine.
Patients (or Materials) and Methods: White male mice of NMRI-
Haan strain, with body weight of 20 to 24 g, were used in this study. 
Analgesic effect of morphine was estimated by the hot plate method. 
Analgesic effect of morphine (2 mg/kg) (administered by subcutane-
ous and intramuscular route of administration) with and without 
pretreatment with MKH-Na (4 mg/kg) and MKH-Me (4 mg/kg) was 
measured.
Results: Administration of MKH-Me before subcutaneous admin-
istration of morphine increased the morphine analgesic effect, but 
the increase was not statistically significant. At the same time the 
administration of MKH-Na did not affected morphine analgesic 
effect. Analgesic effect of morphine was increased when morphine 
